---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Sodium-glucose cotransporter-2 inhibitors and other off-label therapies"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Sodium-glucose cotransporter-2 inhibitors and other off-label therapies. Topics: EASL-EASD-EASO recommendation on SGLT2 inhibitors and metformin as MASH-targeted therapy; EASL-EASD-EASO statement on statins, fibrates, ezetimibe, and silymarin as MASH treatment; ADA Standards of Care 2026: glucose-lowering therapies other than pioglitazone and GLP-1 RAs in adults with type 2 diabetes and MASLD; AASLD 2023 practice guidance on SGLT2 inhibitors, metformin, ursodeoxycholic acid, DPP-4 inhibitors, statins, and silymarin; 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/sodium-glucose-cotransporter-2-inhibitors-and-other-off-label-therapies"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Sodium-glucose cotransporter-2 inhibitors and other off-label therapies

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Sodium-glucose Cotransporter-2 Inhibitors and Other Off-label Therapies

<a id="topic-2.2.2.1.5-1"></a>

### EASL-EASD-EASO recommendation on SGLT2 inhibitors and metformin as MASH-targeted therapy

> “There is insufficient evidence to recommend the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors or metformin as MASH-targeted therapies; however, they are safe to use in MASLD and should be used for their respective indications, namely type 2 diabetes, heart failure and chronic kidney disease (LoE 3, strong recommendation, strong consensus).”
> “Controlled clinical trials with liver histological endpoints are currently not available.”
> “Currently, there is no evidence that metformin alone can improve histology in MASH.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.5-2"></a>

### EASL-EASD-EASO statement on statins, fibrates, ezetimibe, and silymarin as MASH treatment

> “Nonetheless the efficacy of statins, specifically for treating MASH, cannot be established, since there are no large RCTs of statins with histological endpoints. The same holds true for fibrates and ezetimibe.”
> “Silymarin (an extract of milk thistle) may improve liver enzymes but the few, small, RCTs available”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.5-3"></a>

### ADA Standards of Care 2026: glucose-lowering therapies other than pioglitazone and GLP-1 RAs in adults with type 2 diabetes and MASLD

> “In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH.”
> “reduce hepatic steatosis, but their effects on steatohepatitis remain unknown.”
> “However, these agents have either failed to improve steatohepatitis in paired-biopsy studies (metformin) or have no RCTs with liver histological end points (i.e., sulfonylureas, glitinides, dipeptidyl peptidase 4 inhibitors, or acarbose).”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.5-4"></a>

### AASLD 2023 practice guidance on SGLT2 inhibitors, metformin, ursodeoxycholic acid, DPP-4 inhibitors, statins, and silymarin

> “Available studies evaluating the role of SGLT-2i in the treatment of NAFLD/NASH are limited by relatively small sample sizes and lack of histological outcomes.”
> “Within these limitations, available data suggest SGLT-2i improve hepatic steatosis; however, the therapeutic impact of SGLT-2i on liver histology needs to be better defined.”
> “Metformin, ursodeoxycholic acid, dipeptidylpeptidase-4, statins, and silymarin are well studied in NASH and should not be used as a treatment for NASH as they do not offer a meaningful histological benefit.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.5-5"></a>

### Dapagliflozin phase 3 trial (DEAN): design, population, and setting

> “Multicentre, double blind, randomised, placebo controlled trial.”
> “Six tertiary hospitals in China from 23 November 2018 to 28 March 2023.”
> “154 adults with biopsy diagnosed MASH, with or without type 2 diabetes.”
> “All participants were randomly assigned to receive 10 mg orally of dapagliflozin or matching placebo once daily for 48 weeks.”
> “A total of 33% participants (51/154) had stage F1 fibrosis, 45% (70/154) had stage F2, and 19% (29/154) had stage F3.”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="topic-2.2.2.1.5-6"></a>

### Dapagliflozin phase 3 trial (DEAN): histologic results at 48 weeks, intention-to-treat analysis

> “Analyses used the intention-to-treat dataset.”
> “MASH improvement without worsening of fibrosis was reported in 53% (41/78) of participants in the dapagliflozin group and 30% (23/76) in the placebo group (risk ratio 1.73 (95% confidence interval (CI) 1.16 to 2.58); P=0.006).”
> “MASH resolution without worsening of fibrosis occurred in 23% (18/78) of participants in the dapagliflozin group and 8% (6/76) in the placebo group (risk ratio 2.91 (95% CI 1.22 to 6.97); P=0.01). Fibrosis improvement without worsening of MASH was reported in 45% (35/78) of participants in the dapagliflozin group, as compared with 20% (15/76) in the placebo group (risk ratio 2.25 (95% CI 1.35 to 3.75); P=0.001).”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="topic-2.2.2.1.5-7"></a>

### Dapagliflozin phase 3 trial (DEAN): limitations stated by the authors

> “Firstly, our primary endpoint was MASH improvement without worsening of liver fibrosis instead of MASH resolution without worsening of fibrosis or fibrosis improvement without worsening of MASH according to the guidance of FDA”
> “Secondly, the current trial was conducted in a Chinese population, which limits the broader generalisability of the conclusion.”
> “Finally, because of the scarcity of major adverse liver outcomes (eg, cirrhosis and hepatocellular carcinoma), large scale and long term trials are needed to further confirm these effects.”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
